Bioelectronic Medicine: A New Horizon for Difficult‐To‐Treat Rheumatoid Arthritis

The management of rheumatoid arthritis (RA) remains a profound clinical challenge, particularly for patients who are refractory to conventional therapies, often categorized as having difficult‐to‐treat RA (D2T RA) [1]. Despite significant advances in pharmacotherapy, the complexity of RA—characterized by intricate immune dysregulation, such as the dysregulation of programmed cell death in fibroblast‐like synoviocytes [2]—often renders achieving sustained clinical remission a difficult milestone. The physical, emotional, and social toll of this chronic disease is vast, significantly impacting patients' mental health, causing severe fatigue, and lowering their overall quality of life [3].

Current treatment paradigms rely heavily on biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs). However, while these drugs successfully control disease activity in many patients, they are fundamentally immunosuppressive. Although these agents are molecularly targeted, current clinical practice still lacks sufficiently reliable biomarkers to guide individualized treatment selection, highlighting the crucial distinction between molecular targeting and true precision medicine [4]. Furthermore, the systemic nature of these pharmacological interventions carries substantial risks. This is especially concerning in aging populations, where the use of b/tsDMARDs is accompanied by heightened risks of serious infections and the complex challenge of malignancy management [5]. Specifically, targeted therapies such as tofacitinib have been linked to significant age‐ and comorbidity‐dependent risks for major adverse cardiovascular events (MACE), malignancies, and serious infections [6].

In this context, the recent publication of the RESET‐RA trial [7] heralds an emerging therapeutic modality: bioelectronic medicine. Instead of deploying broad‐acting chemical agents, this approach utilizes a surgically implanted device to deliver targeted, daily electrical stimulation to the cervical vagus nerve. By modulating the body's innate “inflammatory reflex,” vagus nerve stimulation (VNS) reduces the overproduction of pro‐inflammatory cytokines without globally suppressing the immune system—a promising mechanism, though these observations must be qualified by the trial's duration and sample size [7]. The trial results are promising for a difficult‐to‐treat population. At 3 months, significantly more patients in the active stimulation group achieved an ACR20 response compared to the sham group (35.2% vs. 24.2%, p = 0.0209). Notably, this clinical benefit increased over time, with ACR20 response rates climbing to 50.0% at 6 months and 52.8% at 12 months [7]. While device‐related serious adverse events in the trial were rare (1.6%), entirely perioperative, and fully resolved, integrating this therapy into clinical practice requires carefully addressing device‐related considerations, including surgical risks, perioperative complications, potential infection risks, device maintenance, cost, patient preference, and access. Furthermore, interpretation of the long‐term efficacy must acknowledge the duration of the sham‐controlled phase and the limitations of longer‐term open‐label follow‐up data. Future studies should evaluate additional outcomes beyond ACR20, including ACR50/70, DAS28 remission or low disease activity, patient‐reported outcomes, structural outcomes, and the durability of response [7].

For the difficult‐to‐treat RA population—those who have exhausted multiple b/tsDMARDs and remain symptomatic—this represents a potentially clinically meaningful option. As we continue to grapple with the limitations and toxicities of our current pharmacopeia, targeted neuroimmune modulation offers a promising, non‐pharmacologic pathway. Ultimately, bioelectronic interventions should be viewed as a promising option for selected patients with difficult‐to‐treat RA, pending further data on long‐term safety, comparative effectiveness, cost‐effectiveness, and optimal patient selection [7].

Author Contributions

Tang‐Kai Cheng: conceptualization, writing – original draft. Hsi‐Kai Tsou: writing – review and editing, supervision.

Funding

The authors have nothing to report.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.